Status and phase
Conditions
Treatments
About
The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced solid tumors.
Enrolment into the Ph 1 part is completed.
The Phase 2 parts (Part B) are cohort expansions with visugromab (CTL-002) in combination with a defined CPI at a fixed dose into seven different solid tumor indications.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Main Inclusion Criteria:
Main Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
274 participants in 2 patient groups
Loading...
Central trial contact
Eugen Leo, MD, PhD, MBA / CMO; Petra Fettes, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal